Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1440
    Keywords: Hypothalamic disease ; pituitary tumours ; pituitary insufficiency ; secondary hypothyroidism ; thyrotropin (TSH) ; thyrotropin releasing factor (TRF) ; Hypothalamische Erkrankungen ; Hypophysentumoren ; Hypophysenvorderlappeninsuffizienz ; Sekundäre Hyperthyreose ; Thyreotropin (TSH) ; Thyrotropin Releasing Faktor (TRF)
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung 1. Die Antworten der Serum-TSH-Spiegel (Thyreoidea-stimulierendes Hormon) auf TRF-Injektion (Thyrotropin Releasing Factor) bei 8 Normalpersonen und 37 z. T. zweimal untersuchten Patienten mit hypophysärer oder hypothalamischer Erkrankung werden mitgeteilt. 2. Hypophysektomierte Patienten mit intrasellären Tumoren (N=12) zeigten keine oder nur subnormale Anstiege der TSH-Spiegel. 3. Von 9 präoperativ untersuchten Patienten mit intrasellärem HVL-Adenom hatten 3 eine sekundäre Hypothyreose. Diese 3 reagierten dennoch mit einem normalen Anstieg der TSH-Spiegel. Dieser Befund schränkt die diagnostische Wertigkeit der TRF-Belastung zur Differenzierung hypophysärer und hypothalamischer sekundärer Hypothyreosen ein. Die 6 euthyreoten Patienten dieser Gruppe zeigten erwartungsgemäß einen normalen TSH-Anstieg. 4. Bei den Patienten mit sekundärer Hypothyreose bei suprasellärem Tumor oder hypothalamischer Erkrankung (N=7) fand sich mit einer Ausnahme ein normaler oder ein erhöhter TSH-Anstieg. Die Bedeutung des Ausschlusses einer primären Hypothyreose wurde dargestellt, da diese Erkrankung ebenfalls durch erhöhte TSH-Anstiege bei TRF-Belastung charakterisiert ist. 5. Je ein Patient aus der Gruppe der aktiven (N=7) und der behandelten (N=6) Akromegalie zeigten einen nicht auf eine primäre Hypothyreose zurückführbaren erhöhen TSH-Anstieg, dessen Rolle für das gehäufte Auftreten einer Struma bei Akromegalie zu diskutieren ist.
    Notes: Summary 1. The response of the serum TSH levels after i.v. administration of 500 µg TRF have been determined in normal controls (n=8) and in 37 patients with pituitary tumour or hypothalamic disease. 2. Following hypophysectomy in patients with intrasellar tumours (n=12), the increment in TSH levels after TRF was absent or diminished. 3. Secondary hypothyroidism was found pre-operatively in 3 of 9 patients with intrasellar pituitary adenoma. In these 3 patients, however, a normal TSH response to TRF was found. This result diminishes the diagnostic value of the TRF test regarding the distinction of pituitary and hypothalamic secondary hypothyroidism. A normal TSH response was found, as expected, in the 6 euthyroid patients of this group. 4. The TSH response was found to be normal or elevated in all but one of 7 patients with secondary hypothyroidism due to suprasellar tumour or hypothalamic disease. Primary hypothyroidism is also characterized by an increased TSH response and has to be excluded. 5. Among the patients with active (n=7) or treated (n=6) acromegaly, increased TSH response was found twice, i.e. in one patient of each of the two groups. In both patients, primary hypothyroidism could be excluded. The relevance of this increased TSH response for goitrogenesis in acromegaly is discussed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Diabetologia 13 (1977), S. 99-104 
    ISSN: 1432-0428
    Keywords: Prolactin ; insulin release ; glucose tolerance ; pituitary tumours ; pancreas perfusions ; bromocriptine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in a second OGTT. — Human PRL or CB 154 had no significant influence on insulin release due to glucose in the perfused rat pancreas. — These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...